Oncology

Ten Reasons Why Biosimilar Candidates Should Not Be Tested for Clinical Efficacy

October 31, 2020

Sarfaraz K. Niazi, PhD

Article

The FDA may require comparative clinical efficacy for biosimilar approval, but on top of all the other required and available evidence, these trials add little value, Sarfaraz K. Niazi, PhD, states.

ACR: UHC's New Co-pay Policy Is "Disastrous" for Patients

October 29, 2020

Tony Hagen

Article

The American College of Rheumatology (ACR) has joined with other provider groups in opposing a UnitedHealthcare (UHC) plan that could increase patient out-of-pocket costs.

Mvasi, Kanjinti Add Heft to Amgen's Third-Quarter Sales

October 29, 2020

Tony Hagen

Article

Amgen said its sales results for Mvasi (bevacizumab) and Kanjinti (trastuzumab) give it confidence that the US market for biosimilars is more viable than generally perceived.

Pfizer's Biosimilar Revenues Soar 80%

October 27, 2020

Tony Hagen

Article

The strong growth of biosimilars Pfizer recently launched in the United States are part of the success story, although reference etanercept (Enbrel) sales have seen major erosion.

Alvotech Locks In $65 Million for Biosimilar Development

October 27, 2020

Tony Hagen

Article

With a sizeable round of fresh capital, Alvotech hopes to bring monoclonal antibodies and fusion proteins through the development pipeline.

Europeans Devise Checklist for Promoting Biosimilar Use

October 24, 2020

Deana Ferreri, PhD

Article

European investigators have derived a set of core principals for developing higher utilization of biosimilars.

Biocon Reports Biosimilars Revenue Growth

October 23, 2020

Tony Hagen

Article

Biocon had a busy quarter, which included the launch of a long-acting insulin glargine product (Semglee) in partnership with Mylan.

Sandoz’ Edward Li on Using Filgrastim to Ease the Risk of Febrile Neutropenia

October 20, 2020

Video

Edward Li, PharmD, director of Health Economics and Outcomes Research for Sandoz, discussed how biosimilar filgrastim (Zarxio) used as primary prophylaxis saves money and helps reduce the risk of febrile neutropenia in patients with cancer.

Roche Earnings Hit by Biosimilar Competition, COVID-19

October 16, 2020

Tony Hagen

Article

Roche attributes a $3.83 billion reduction in sales to biosimilar competition.

Thomas Wakim On Neuclone’s Early Dive Into Developing PD-1 Inhibitor Biosimilars

October 15, 2020

Video

Thomas Wakim, strategic analyst for Neuclone, discussed the company’s decision to break into the world of PD-1 inhibitors, its partnership with the Serum Institute in India, and Neuclone’s biosimilar pipeline.

x